A treatment strategy for the failure of the first treatment of the fungus Spirulina.

The treatment strategy for the failure of the first treatment of the fungus fungus circulus (Hp) infection is closely related to various stomach diseases such as stomach inflammation, stomach ulcer, stomach cancer, etc. The development of a sound treatment strategy is particularly critical when initial treatment fails, which contributes to the success rate of follow-up treatment, reduces the risk of disease-related complications and improves the health and quality of life of patients. When initial treatment fails, the process needs to be fully evaluated. Detailed information is provided on the type of drugs used by the patient at the time of the first treatment, the dose, the course of treatment and the dependence of the drug. The failure of many patients may be due to a failure to comply strictly with medical instructions, to take medications on a regular basis, such as leaks, self-reductions or premature withdrawals. If there is a problem of drug dependence, education and communication should be strengthened, with emphasis on the importance of regulating treatment and providing a good basis for subsequent treatment. More in-depth screening of patients is also essential. In addition to regular stomach lenses to detect abdominal pathologies, bacterial culture and drug sensitivity can be tested. Bacteria culture makes it possible to identify the fungus strain of the cholesterol virus infected by the patient and to determine its sensitivity to different antibiotics. This provides a scientific basis for precision in the selection of effective antibiotics and avoids blind use of antibiotics leading to repeated treatment failures and increased bacterial resistance. In the development of re-treatment programmes, due consideration should be given to a number of factors, based on evaluation and examination results. The following principles are generally followed: the first is to replace antibiotics and avoid the use of antibiotics in the first treatment programme in order to reduce the effects of bacterial resistance. For example, if Amosilin and Cracin are used for the first treatment, re-treatment may be considered for other antibiotics such as furanquinone and methazole, subject to the results of the sensitive test. Secondly, there is an increase in the use of drugs in combination, with the use of four combinations of treatments and even more intensive treatment programmes, to extend the treatment to 14 days or more to increase the rate of eradication of cholesterol. Commonly used four combination therapies include proton pump inhibitors (e.g. Omera, Lansola, etc.), americium (e.g. potassium acetate) and two antibiotics. Third, the dose of the drug is adjusted to the patient ‘ s individual circumstances, and for some patients who are more resistant, the dose of antibiotics can be increased, as appropriate, to enhance the effects of microbicide, subject to close monitoring of the adverse effects of the drug. In the process of treatment, the management of patients is crucial. (c) Strengthen health education for patients, inform them of possible adverse reactions and responses during treatment, and increase their compliance with treatment. At the same time, patients are required to maintain good living habits during treatment, such as regular diets, avoidance of consumption of irritating food, cessation of smoking and alcohol, so as to promote gastric mucous membrane repair and improve treatment effectiveness. Upon completion of treatment, the patient is reviewed, and carbon-13 or carbon-14 exhalation tests are used to test the eradication of the claustrophorus after 4 weeks. If the results of the review are still positive, the patient ‘ s situation needs to be further assessed, taking into account the need for re-treatment and the need for more individualized treatment programmes, such as second- and even third-line treatment, and, if necessary, by consulting or referring the relevant expert to a higher-level medical institution. In the light of the above, the failure of the first treatment of the cholesterococcus can be effective in improving the success rate of follow-up treatment, minimizing the long-term health risks to the patient and protecting his or her stomach health through a series of diagnostic strategies, such as comprehensive assessment, in-depth examination, rational development of treatment programmes, enhanced patient management and normative review.